HomeProductsBioactive CompoundsCell CycleChkSra-737
Chemical structure of CAS 1489389-18-5

Sra-737

CAS No.1489389-18-5
MDL No.MFCD30489721
MFC16H16F3N7O
MW379.34
InChI KeyYBYYWUUUGCNAHQ-LLVKDONJSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.1489389-18-5
Product NameSra-737

Associated Conditions

non-Hodgkins lymphoma
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).

Journal of medicinal chemistry • Vol. 59, Issue 11 • 2016
PMID: 27167172DOI: 10.1021/acs.jmedchem.5b01938

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.

Oncotarget • Vol. 7, Issue 3 • 2016
PMID: 26295308PMC: PMC4823038DOI: 10.18632/oncotarget.4919

Studies on D-tetrose metabolism. VI. Crystallization and some properties of D-erythrulose reducatase from beef liver.

Journal of biochemistry • Vol. 78, Issue 3 • 1975
PMID: 5410DOI: 10.1093/oxfordjournals.jbchem.a130936

Documentation